Replies to post #650609 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

So when asked by JAMA Oncology why the comp to 99 was not used for OS, LL said:

[notes crossover], So with that, and with the confounder of pseudo progression vs true progression, what happened eventually was almost 90 percent of the people in the control arm had crossed over

To be clear, the critique called BS on not having presenting the OS vs 99 data and noted the rational as stated by LL.

Comical that somebody citing LL's own words is making a serious mistake.

BTW, the "64 or 99 crossed after progression" and "eventually 90% crossed" statements are not contradictory. As LL stated, psPD confounded this so maybe patients crossed prior to progression. Or maybe later. Or who knows.